✉news BusinessStartups first seen 2 d ago, last 2 d ago, peak #15
Sanofi partners with startup ScionxBio on long-acting RNA drugs
Original: Exclusive: Sanofi taps new startup ScionxBio for long-acting RNA
French pharmaceutical giant Sanofi has struck a deal with newly launched biotech ScionxBio to develop long-acting RNA medicines, according to an exclusive report by Endpoints News. The tie-up signals Sanofi's continued push into RNA-based therapeutics, a field energised by the success of mRNA vaccines. Details of the financial terms and ScionxBio's technology have not yet been disclosed.
Why now: A major pharma company backing an early-stage RNA startup is notable news for the biotech and investment communities.
Rank over time, top of the chart is #1. 6 snapshots from 2 d ago to 2 d ago.
Evidence
- Exclusive: Sanofi taps new startup ScionxBio for long-acting RNA · Endpoints News
API: https://socialmediatrends-api.osmike.com/v1/trends/2864638